Q3 EPS Estimate for Akebia Therapeutics Increased by Analyst

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Equities research analysts at HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a report issued on Thursday, October 30th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will earn $0.01 per share for the quarter, up from their previous forecast of ($0.02). HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q4 2025 earnings at $0.01 EPS, FY2025 earnings at $0.04 EPS, FY2026 earnings at $0.31 EPS and FY2027 earnings at $0.26 EPS.

Several other analysts also recently weighed in on AKBA. Wall Street Zen upgraded Akebia Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Research downgraded Akebia Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Akebia Therapeutics in a research report on Wednesday, October 8th. Finally, BTIG Research dropped their target price on Akebia Therapeutics from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

Akebia Therapeutics Price Performance

Shares of AKBA stock opened at $2.21 on Monday. The company has a quick ratio of 1.84, a current ratio of 1.98 and a debt-to-equity ratio of 1.61. Akebia Therapeutics has a twelve month low of $1.52 and a twelve month high of $4.08. The company has a market cap of $585.97 million, a P/E ratio of -13.00 and a beta of 0.68. The business has a fifty day simple moving average of $2.89 and a 200 day simple moving average of $3.11.

Institutional Investors Weigh In On Akebia Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Akebia Therapeutics by 16.6% in the first quarter. Vanguard Group Inc. now owns 12,685,803 shares of the biopharmaceutical company’s stock valued at $24,357,000 after buying an additional 1,801,603 shares during the period. Geode Capital Management LLC increased its stake in shares of Akebia Therapeutics by 20.7% in the second quarter. Geode Capital Management LLC now owns 6,074,458 shares of the biopharmaceutical company’s stock valued at $22,115,000 after buying an additional 1,043,718 shares during the period. AIGH Capital Management LLC acquired a new stake in shares of Akebia Therapeutics in the first quarter valued at about $5,616,000. MPM Bioimpact LLC acquired a new stake in shares of Akebia Therapeutics in the second quarter valued at about $10,516,000. Finally, Goldman Sachs Group Inc. grew its stake in Akebia Therapeutics by 171.8% during the first quarter. Goldman Sachs Group Inc. now owns 2,724,439 shares of the biopharmaceutical company’s stock worth $5,231,000 after purchasing an additional 1,722,245 shares during the period. Institutional investors and hedge funds own 33.92% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.